Healthify and Novo Nordisk India have launched an AI enabled patient support program designed to assist individuals managing obesity through structured digital interventions, personalised guidance and continuous lifestyle monitoring. The initiative reflects the growing use of artificial intelligence in chronic disease management, where tailored engagement and real time behavioural insights can support sustained improvements in health outcomes. Both organisations stated that the new program aims to help patients adopt healthier routines while improving adherence to treatment plans recommended by healthcare professionals.
According to information shared across industry updates, the program integrates Healthify’s AI driven coaching capabilities with Novo Nordisk India’s long standing focus on obesity care. Obesity has become a rising concern in India due to changing dietary patterns, sedentary lifestyles and increased prevalence of metabolic disorders. The companies indicated that the AI enabled system will provide patients with personalised goals, real time progress tracking and guided behavioural support. This includes structured recommendations on nutrition, physical activity and lifestyle adjustments tailored to the individual’s health profile.
The program is expected to operate as a companion layer to clinical care, allowing doctors to prescribe the digital support system as part of broader treatment plans. Healthify noted that its AI models analyse user inputs, behavioural patterns and daily progress to generate timely nudges that help individuals remain consistent with lifestyle changes. The system also allows for human coach intervention where necessary, creating a hybrid model that combines automated insights with professional support. This is intended to strengthen long term adherence, which is often a challenge in obesity management.
Novo Nordisk India stated that the partnership aligns with its efforts to strengthen patient centric care in chronic metabolic conditions. The company has been expanding initiatives focused on diabetes and obesity, emphasising the need for continuous support beyond traditional clinic visits. By integrating AI driven tools, the organisation believes patients will have better access to structured guidance and sustained motivation, two critical factors influencing clinical outcomes. The initiative also reflects a broader shift in healthcare toward digital therapeutics that complement medical treatment.
Industry reports highlight that the program includes personalised diet plans, activity recommendations, sleep quality monitoring and behaviour modification pathways. These features are supported by Healthify’s AI algorithms, which adapt to patient responses and adjust guidance based on real time data. With obesity often requiring long term lifestyle shifts rather than short term interventions, digital tools that provide daily feedback have become increasingly relevant in India’s healthcare landscape.
Healthify has been strengthening its capabilities in AI driven wellness, including multimodal conversational tools, continuous behavioural learning and personalised habit-building systems. For this program, the company has applied its experience in designing AI models that offer culturally relevant and practical lifestyle support for Indian users. The partnership with Novo Nordisk India extends these capabilities into a clinical context, enabling a structured digital companion for patients undergoing obesity treatment.
The program also aligns with rising global interest in technology assisted obesity care. As newer medications and digital therapeutics become available, healthcare systems are exploring ways to combine pharmacological treatment with behavioural support to maximise effectiveness. Digital platforms can help track progress, identify patterns that hinder adherence and provide timely interventions to prevent lapses. For clinicians, such tools can offer aggregated insights into patient progress and help guide more informed consultations.
According to coverage in healthcare and technology publications, the AI enabled system launched by Healthify and Novo Nordisk India incorporates evidence based frameworks that support behavioural change. Users receive habit formation guidance, educational content and structured routines customised for various stages of their health journey. The program also focuses on long term sustainability, encouraging small daily changes rather than aggressive short term targets. This approach is consistent with medical recommendations that obesity treatment should be gradual, holistic and continuous.
The collaboration is also part of a growing effort to integrate AI in India’s public health and lifestyle disease ecosystem. Chronic conditions such as obesity require repeated touchpoints, ongoing reinforcement and personalised adaptation that traditional care models struggle to provide at scale. Digital tools allow for wider reach, consistent monitoring and cost effective engagement. By combining pharmaceutical expertise with AI driven behavioural support, the program aims to bridge gaps in patient engagement that often affect treatment success.
Healthify and Novo Nordisk India have indicated that the initiative is structured to meet regulatory and ethical standards for patient data handling. Given the sensitivity of health information, the companies noted that robust privacy protocols and secure systems are in place. As more digital health programs expand across India, compliance with medical data regulations has become a priority for both technology providers and pharmaceutical companies.
With lifestyle diseases continuing to rise in India, healthcare partnerships involving AI tools are expected to grow. The program launched by Healthify and Novo Nordisk India represents an example of how digital platforms can complement clinical therapy and support broader public health goals. As adoption increases, the role of AI in personalised patient support may become a defining component of long term disease management strategies.